396 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific … and the Subsidiaries and designed such disclosure controls and procedures to provide reasonable assurance that information required to be disclosed
8-K
EX-10.2
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
Closing Date (i) the legal opinion of Paul Hastings LLP, dated as of such Closing Date, including, without limitation, a negative assurance letter, (ii
424B5
SEEL
Seelos Therapeutics Inc
20 May 24
Prospectus supplement for primary offering
4:16pm
as part of the hearing process; however, there can be no assurance the Panel will grant any request for continued listing or that we will be able … , which may include, among other options, effectuating a reverse stock split. There can be no assurance that we will be able to regain compliance
8-K
0z5jkqg3q8ih vicuj04
3 May 24
Entry into a Material Definitive Agreement
5:06pm
424B3
xumeqk5vodzx3d0
15 Mar 24
Prospectus supplement
4:15pm
8-K
EX-10.1
9of3lsd8 o0d2h4i
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
djowue ubj55
30 Jan 24
Prospectus supplement for primary offering
6:05am
8-K
EX-1.1
wxwk0
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
ong9atqmzkr mgv49zo
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
946slf8voh6jjt7
28 Nov 23
Prospectus supplement for primary offering
4:06pm